Skip to main content
TECX logo

TECX · Tectonic Therapeutic, Inc.

Track TECX — free
$21.04 +0.00 (+0.00%) At close · Nov 19
Market Cap
$419.71M
Shares
19.95M
Volume · Nov 19 87.18K Avg daily vol (3M) 210.71K

Price & Indicators

 

Key stats

Close
$21.04
Open
$21.01
Day range
$20.61–21.55
52-week closing range
$17.93–37.93
Average volume, 30 days
175K
Short interest
2.4M · 11.9% of shares · 13.7 days
Short volume, last session
68%
Last earnings
Feb 24, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Nov 11
Investor event
TX45 Phase II data expected by end of January

Tectonic Therapeutic expects TX45 Phase II data by end of January and plans PHILD interim data in the second half of 2027, with cash runway through the first quarter of 2029.

4 source passages
All right, we can get started, so we can make sure to get through all of our questions. But great to be here with Tectonic Therapeutic. We have a Catalyst Rich 2027. It'll start with our... TX45, our lead program, will have Phase II data by end of January. We are actively enrolling our PHILD study with TX45, and we expect interim data from that study, which is a single-arm study of about 20 to 25 patients, second half of 2027. Cash Runway to first quarter of 2029, which should really cover both getting through our APEX data and CPCPH, Group 2PH, PHILD, and the Phase 1 and the Phase 2 for HHT. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
TX45 APEX enrollment completed; January 2027 topline results expected

Tectonic Therapeutic completed TX45’s APEX Phase 2 enrollment with 191 patients across 14 countries in June 2026 and expects topline results by the end of January 2027. The IDMC recommended continuing the study without modification.

Net loss $21.35M Diluted EPS -$1.08
Read from the MD&A section
2 source passages
In June 2026, we completed enrollment in the APEX Phase 2 clinical trial, having enrolled 191 patients across 14 countries, with approximately 72% of enrolled patients in the enriched population of CpcPH patients with a PVR>3 Wood Units at baseline. In July 2026, the Independent Data Monitoring Committee (“IDMC”) met to review unblinded safety and efficacy data from the TX45 APEX Phase 2 clinical trial, including approximately 80% of the expected patient exposure. The IDMC recommended the continuation of the study without modification. We expect topline results from the APEX Phase 2 clinical trial by the end of January 2027. Open the document at this passage
Nov 5
Current report 8-K
APEX results expected amid cash runway into Q1 2029

Tectonic reported favorable TX2100 results, dosed the first patient in the TX45 ALPINE trial and expects APEX topline results by the end of January 2027. Cash of $234.7 million at September 30, 2026 supports runway into Q1 2029.

Completed an acquisition or sale of assets
4 source passages
Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers Tectonic dosed the first PH-ILD patient in the TX45 ALPINE Phase 2a clinical trial. Topline results from the APEX Phase 2 clinical trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) are anticipated by the end of January 2027 Cash and cash equivalents of $234.7 million as of September 30, 2026, including approximately $22.3 million in net proceeds raised from an at-the-market offering for the three months ended September 30, 2026, is expected to provide cash runway into Q1 2029 Open the document at this passage
Sep 29
Current report 8-K
Other events

Tectonic Therapeutic reported favorable TX2100 Phase 1a safety and tolerability, with no deaths, serious adverse events or severe treatment-emergent adverse events. FDA granted Fast Track designation; Phase 1b and Phase 2 starts are planned by year-end 2026 and early 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$88.10M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-16.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$234.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.3%
Year over year · more shares
Price change (1Y)
+12.2%
Trailing year
Short interest
11.9%
Latest settlement · 13.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −7%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 16%
mid-range
Momentum
relative strength
Weak
1-month return 0%
trailing
6-month return −27%
trailing
YTD return +1%
this year
Relative strength −22%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $23 › 200d $28 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.91% of shares out · ▲ +6.8% MoM · 13.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
116 holders — mid 3-yr range
Squeeze score 78
high risk · 0–100
Fundamentals
Strong
EPS growth +41%
Y/Y
Free cash flow $-60.3M
Balance sheet $253.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −50%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
16% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $23 › 200d $28 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.91% of shares out · ▲ +6.8% MoM · 13.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
116 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $18 Now $21 · 16% Range high $38
vs 200-day avg -25% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TECX
Tectonic Therapeutic, Inc.
this stock
$419.71M +0.9% — — 11.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
116
% held
71.6%
Net QoQ
+325.7K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
138
View
Short & Settlement
Short Interest Rising
Shares short
2.4M
Days to cover
13.7d
Change
+151.0K sh
View
Short Volume
Short vol %
68%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$21.3K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
43.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-74.2M
EPS diluted
$-4.05
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
16

Tectonic Therapeutic expects TX45 Phase II data by end of January and plans PHILD interim data in the second half of 2027, with cash runway through the first quarter of 2029.

View
Proposed Sales
Value
$11.5K
Shares
493
Filed
Sep 30, 2026
View
Exempt Offerings
Offering
$185.0M
Filed
Feb 14, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
Tectonic Therapeutic to Participa…
Published
Nov 9, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
TECX +0.0% -0.2% -27.2% +6.4% +0.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +5.5% +6.1% -21.5% +11.6% -4.1%
Key facts CIK 1681087 CUSIP 878972108 13F (30d) 116 filings 110 filers Visit website Investor relations